Injuries are responsible for more deaths per year than HIV/AIDS, tuber culosis and malaria combined. [1] Furthermore, each year ~4 million people die as a result of traumatic injuries and violence worldwide. In South Africa, trauma is a major concern, with violence and road traffic accidents being the fifth and seventh leading causes of death respectively. [2] Antifibrinolytic agents have been used in trauma and major surgery to prevent fibrinolysis and reduce blood loss.
We summarise the evidence from an updated Cochrane review [3] investigating the effect of antifibrinolytic drugs in patients with acute traumatic injury.
Methods
The review authors conducted comprehen sive literature searches in January 2015. All randomised controlled trials comparing anti fibrinolytic agents (aprotinin, tranex amic acid (TXA), epsilon aminocaproic acid and amino methylbenzoic acid) administered after acute traumatic injury were included. No restric tions were made with regard to language, date or publication status. Standard Cochrane methods for independent data screening and eligibility assessment, data extraction and risk ofbias evaluation were followed.
Results
Three randomised controlled trials were inclu ded, of which two (n=20 451) assessed the effect of TXA. The Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH)2 trial (n=20 211), [4] the larger of the two, was conducted in 40 countries and included patients with a variety of trauma types; the other specifically investigated patients with traumatic brain injury (TBI) (n=240). The third trial assessed aprotinin in participants with major bony trauma and shock. All three trials [3] provided data for metaanalysis.
Antifibrinolytics reduced the risk of death by 10% (relative risk (RR) 0.90, 95% confi dence interval (CI) 0.85 0.96; three trials, highquality evidence) compared with placebo. It should be noted that this estimate was largely based on the results of CRASH2, a metho dologically rigorously conducted trial.
The In South Africa, trauma is a major concern, with violence and road traffic accidents being the fifth and seventh leading causes of death, respectively. Antifibrinolytic agents have been used in trauma and major surgery to prevent fibrinolysis and reduce blood loss. We highlight an updated Cochrane review investigating the effect of antifibrinolytic drugs in patients with acute traumatic injury. The review authors conducted comprehensive literature searches in January 2015 with regard to all randomised controlled trials comparing antifibrinolytic agents after acute traumatic injury. Three randomised controlled trials, of which two (n=20 451) assessed the effect of tranexamic acid (TXA), were included. The authors concluded that TXA safely reduces mortality in trauma with bleeding without increasing the risk of adverse events. TXA should be administered as early as possible, and within 3 hours of injury. There is still uncertainty with regard to the effect of TXA on patients with traumatic brain injury; however, ongoing randomised controlled trials should shed more light on this. [3 ] with permission. † Population: treating bleeding trauma patients; settings: hospital settings in 40 countries; [4] intervention/comparison: antifibrinolytic drugs v. placebo. ‡ Grade = working group grades of evidence; high quality = further research is very unlikely to change our confidence in the estimate of effect; moderate quality = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality = we are very uncertain about the estimate. § Downgraded one level for imprecision: estimate based on few events and wide CIs. 
Conclusion
The review authors concluded that TXA safely reduces mortality in trauma with bleeding, without increasing the risk of adverse events. TXA should be given as early as possible and within 3 hours of injury. There is still uncertainty with regard to the effect of TXA on patients with TBI; however, ongoing randomised controlled trials should shed more light on this. Evidence from this review has been incorporated into trauma clinical practice guidelines [5] by the National Institute for Health and Care Excellence (NICE) in the UK, which has made recommendations for TXA use in both inhospital and prehospital settings.
